Interview: Carl Firth, CEO, ASLAN Pharmaceuticals, Taiwan
The CEO of ASLAN Pharmaceuticals discusses the fundamental changes that need to occur in the treatment of serious illnesses, the advantages of building a second branch in Taiwan, and the…
ASLAN is an Asia enabled pharmaceutical company that develops novel medicines for global markets.
1. ASLAN inlicenses preclinical drugs that are up to 6-12 months from the clinic
2. ASLAN uses its own financial resources and high quality CRO facilities to perform preclinical, Phase 1 and 2 studies on the partnered compounds
3. ASLAN gets Proof of Concept (PoC) for the partnered compounds in Asia
4. ASLAN outlicenses PoC compounds back to partner for global development and launch
Walsin Xinyi Building, 11/F
No. 1, Songzhi Road
Taipei 11047, Taiwan 11047
Tel: +886 2 8729 2180
Fax: +886 2 8729 2333
http://www.aslanpharma.com/index.html
The CEO of ASLAN Pharmaceuticals discusses the fundamental changes that need to occur in the treatment of serious illnesses, the advantages of building a second branch in Taiwan, and the…
Ingo Brandenburg, managing director of Bayer Taiwan, brings over two decades of international pharmaceutical experience spanning Asia, Latin America, and Europe. With previous leadership roles, he has cultivated a deep…
Taiwan is, in many ways, a healthcare model for Asia. The island has had universal health coverage for over 30 years and Taiwan’s life expectancy today is almost 81 years,…
Vincent Tong, Managing Director of MSD Taiwan, brings two decades of pharmaceutical expertise to his second tenure leading the organisation in Taiwan. Having first served in Taiwan in 2008, Tong…
Professor Pan Chyr Yang is a clinician-scientist with an MD and PhD in pulmonary medicine, holding joint appointments at Academia Sinica and former university leadership roles in National Taiwan University. Recognised…
With its thriving innovation ecosystem and growing global visibility, Taiwan is fast emerging as one of Asia’s most dynamic biotechnology hubs. At the forefront of this transformation is Wallace Lin,…
Dr Chih-Kang Chiang, Director-General of the TFDA, shares how Taiwan is redefining regulation through science, transparency, and international collaboration. Combining his backgrounds in medicine, toxicology, and law, he leads efforts…
After more than two decades in Silicon Valley, Dr Jeng Her returned to Taiwan with a bold ambition: to help transform its emerging biotech sector into a globally recognised force…
Dr Wen-Liang Huang, General Manager of Ever Supreme Biotechnology, brings over 40 years of clinical cardiology experience to biopharmaceutical leadership. Recruited by the company’s founder, his medical background informs the…
Dr Chiu-Heng Chen (John), CEO of LaunXP, brings a unique perspective to oncology drug development shaped by his personal experience with cancer during his PhD in the UK. Holding advanced…
Taiwan’s healthcare system stands among the most advanced and accessible in Asia, yet, as the IRPMA’s CW Chen points out, sustainability is now the central concern. Drawing on a career…
Carl Wegner, President of AmCham Taiwan, reflects on his first months in the role, highlighting the chamber’s advocacy mission, the strength of its committees, growing US–Taiwan engagement, and major opportunities…
As a part of the World Health Organisation’s (WHO) COVID-19 Technology Access Pool (C-TAP), the Medicines Patent Pool has signed a worldwide license with Medigen Vaccine Biologics (MVC) for its…
See our Cookie Privacy Policy Here
